Prolight Diagnostics
Aileen McGettrick currently serves as Chief Scientific Officer and board member at Prolight Diagnostics since October 2023. Previously, Aileen held the position of Head of Product Development at Psyros Diagnostics from June 2018 to September 2023, after co-founding the company in 2018 to create advanced point-of-care diagnostic solutions. Aileen’s experience includes various roles at Novartis, including Group Head of Assay Development and Fellow, as well as leadership positions at Vivacta and Delphic Diagnostics. Aileen began a postdoctoral fellowship at the Joslin Diabetes Center and the University of Oxford, following a robust academic background culminating in a Doctor of Philosophy in Biochemistry and Molecular Biology/Genetics from the University of Oxford, and also holds a Master of Research in Biotechnology from the University of Kent and a Bachelor of Science in Biology from the University of Southampton.
This person is not in any teams
This person is not in any offices
Prolight Diagnostics
1 followers
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction. The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.